An Update on Eradication of Helicobacter Pylori in Iran: A Review.
Background: Helicobacter pylori, the most prevalent infection in the world, has great importance due to being related to peptic ulcer disease, gastric metaplasia, dysplasia, and even gastric adenocarcinoma or mucosa-associated lymphoid tissue (MALT) lymphoma. The standard H. pylori eradication regim...
| Publicado en: | Middle East Journal of Digestive Diseases Vol. 16; no. 3; pp. 147 - 155 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | review tables/charts Journal Article |
| Publicado: |
Iranian Association of Gastroenterology & Hepatology
Jul2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=180456118&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 180456118 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 20085230 BG4K jtl: Middle East Journal of Digestive Diseases issn: 20085230 maglogo: N pubinfo: dt: Jul2024 vid: 16 iid: 3 pid: 70725 pub: Iranian Association of Gastroenterology & Hepatology artinfo: ui: 180456118 180456118 180456118 10.34172/mejdd.2024.389 180456118 ppf: 147 ppct: 8 formats: fmt: @attributes: type: P tig: atl: An Update on Eradication of Helicobacter Pylori in Iran: A Review. aug: au: Ebrahimi, Mahboobe Fakheri, Sepehr Tirgar Aeeni, Faezeh Taghvaei, Tarang Firoozi, Mehdi Saberi Fakheri, Hafez affil: Gut and Liver Research Center, Non-communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran sug: subj: Helicobacter Infections Drug Therapy Helicobacter Infections Prevention and Control Disease Eradication Iran Antibiotics, Combined Therapeutic Use Drug Therapy, Combination Antibiotics Therapeutic Use Antiinfective Agents, Quinolone Therapeutic Use Clarithromycin Therapeutic Use Ofloxacin Therapeutic Use ab: Background: Helicobacter pylori, the most prevalent infection in the world, has great importance due to being related to peptic ulcer disease, gastric metaplasia, dysplasia, and even gastric adenocarcinoma or mucosa-associated lymphoid tissue (MALT) lymphoma. The standard H. pylori eradication regimen is based on antibiotic susceptibility testing. If susceptibility testing is not available, a standard treatment regimen will be recommended based on records of H. pylori resistance rates to antibiotics in a region or locally proven highly effective regimens (equal to or higher than 90% eradication rate). The aim of this review was to define suitable recommendations for local treatment in different cities of Iran. Methods: This review article consists of randomized controlled trials related to H. pylori eradication in Iran. Data including the kind of therapy, number of patients and per-protocol H. pylori eradication rates were recorded in data gathering forms. Data search was conducted in PubMed and Google Scholar databases from 2018 to December 2023. Results: According to our review of Iranian articles regarding first-line H. pylori eradication regimens, these treatment protocols could be recommended: Bismuth-clarithromycin quadruple therapy in Ardabil, bismuth-clarithromycin quadruple therapy with probiotics in Birjand, standard triple therapy in Ilam, bismuth quadruple therapy or bismuth triple therapy or concomitant regimen in Sari, sequential therapy in Tehran and bismuth quadruple therapy in Yazd. These regimes can be extended to other regions that have a similar situation. According to the reports of Iranian researchers, a quinolone-containing regimen (levofloxacin preferred) is recommended for second-line eradication therapy. Conclusion: Various H. pylori eradication regimens can be used as first-line therapy; however, choices for second-line therapy are limited. We recommend the quinolone-containing regimens as the preferred second-line therapy. pubtype: Academic Journal doctype: review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|